{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidiklkihp6pzmq2jhrup64iyzglynbybq4hrkppjmdzjl4aj3qn3a",
    "uri": "at://did:plc:7ltlvigjik37fxbx2bat4p22/app.bsky.feed.post/3mndrtskvvjb2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifhsdp66bvwhjhw6g3u57z2lak5mhrdm3uql7fb5dyadwjc2a3zhu"
    },
    "mimeType": "image/jpeg",
    "size": 52212
  },
  "path": "/infectious-diseases/fda-approves-covid-19-ensitrelvir/",
  "publishedAt": "2026-06-02T23:38:20.000Z",
  "site": "https://refractor.io",
  "tags": [
    "Continue Reading",
    "Infectious Diseases",
    "Illnesses and conditions",
    "Body and Mind",
    "FDA",
    "Coronavirus (COVID-19)",
    "Drug development",
    "Virus",
    "Transmission"
  ],
  "textContent": "The US has its first and only oral COVID-19 post-exposure prophylaxis (PEP) on its way, after a Phase III trial of the drug ensitrelvir met goals required for approval by the US Food and Drug Administration (FDA).\n\nContinue Reading\n\n**Category:** Infectious Diseases, Illnesses and conditions, Body and Mind\n\n**Tags:** FDA, Coronavirus (COVID-19), Drug development, Virus, Transmission",
  "title": "FDA approves pill that cuts COVID risk nearly 70%"
}